Spun out of MIT, the company is engineering a new class of biomolecules at 10x lower cost and drastically increased scale to advance gene editing toward cures for complex diseases. “We believe curing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback